Pre-market hot trades in US stocks: LightInTheBox pre-market down 9.86%; Guardian Metal Resources pre-market down 9.86%

Popular Pre-Market Trades in US Stocks LightInTheBox, down 9.86% in pre-market trading, has no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Guardian Metal Resources is down 9.86% in pre-market trading. Based on recent key news: On March 27, Lars Bader disclosed that his voting rights shareholding in Guardian Metal Resources decreased to 3.48% from 4%. This change raised market concerns about the company's governance structure, leading to a decline in stock price. On March 27, UCAM reported that its voting rights shareholding in Guardian Metal Resources fell from 28.31% to 24.44%. This significant decrease in shareholding further exacerbated market unease, pushing the stock price down. The market expressed concerns about changes in the company's governance structure, leading to stock price volatility. Top Gainers in Pre-Market Trading in US Stocks Iterum Therapeutics is up 158.15% in pre-market trading. Based on recent key news: On March 27, Iterum Therapeutics announced it had filed for liquidation in the High Court of Ireland, appointing Damien Murran and Jennifer McMahon from Teneo Restructuring as joint provisional liquidators to oversee the liquidation process. This move led to significant volatility in the company's stock price. On March 27, the company released a related announcement through the EDGAR system, confirming the details of the liquidation application and emphasizing its focus on treating multi-drug resistant pathogen infections. On March 28, Iterum Therapeutics initiated the liquidation process and announced leadership changes, further increasing market uncertainty about the company's future, impacting the stock price. The pharmaceutical industry faces policy and market challenges. PMGC is up 83.76% in pre-market trading. Based on recent key news: On March 27, PMGC Holdings signed a third amended licensing agreement with South Korean biotechnology company MOA Life Plus through its subsidiary Northstrive Biosciences. This amendment adjusted the timelines and key development milestones for the EL-32 and EL-22 human clinical projects to better align with both parties' research, development, and regulatory expectations. This news drove a significant increase in PMGC's stock price. On March 27, PMGC Holdings announced that the amended agreement signed by its subsidiary Northstrive Biosciences with MOA Life Plus would replace the original development milestones and timelines to better align with the current development plan. PMGC will pay consideration to MOA within 30 days of the agreement's execution and the effective date This update further enhances market confidence in the future development of PMGC. On March 27, PMGC Holdings, through its subsidiary Northstrive Biosciences, signed a revised agreement with MOA Life Plus covering the EL-32 and EL-22 projects, aimed at preventing muscle loss during weight loss treatments. EL-22 is described as Northstrive's main asset, utilizing an engineered probiotic approach. This news has filled investors with expectations for PMGC's innovative capabilities, driving the stock price up. The biotechnology industry has recently performed strongly, with significant capital inflows. Zeta Network rose 40.61% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation